MA42060A - Domaines de type iii de fibronectines fixant l'antigène membranaire spécifique de la prostate - Google Patents
Domaines de type iii de fibronectines fixant l'antigène membranaire spécifique de la prostateInfo
- Publication number
- MA42060A MA42060A MA042060A MA42060A MA42060A MA 42060 A MA42060 A MA 42060A MA 042060 A MA042060 A MA 042060A MA 42060 A MA42060 A MA 42060A MA 42060 A MA42060 A MA 42060A
- Authority
- MA
- Morocco
- Prior art keywords
- membranary
- fibronectines
- antigen
- specific
- type iii
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562157772P | 2015-05-06 | 2015-05-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42060A true MA42060A (fr) | 2018-03-14 |
Family
ID=57217949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042060A MA42060A (fr) | 2015-05-06 | 2016-05-06 | Domaines de type iii de fibronectines fixant l'antigène membranaire spécifique de la prostate |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10844111B2 (fr) |
| EP (1) | EP3292222B1 (fr) |
| JP (2) | JP7366518B2 (fr) |
| KR (1) | KR102625793B1 (fr) |
| CN (1) | CN107849116A (fr) |
| AU (2) | AU2016258174B2 (fr) |
| CA (1) | CA2985138A1 (fr) |
| EA (1) | EA201792441A2 (fr) |
| HK (1) | HK1253005A1 (fr) |
| IL (1) | IL255425B2 (fr) |
| MA (1) | MA42060A (fr) |
| WO (1) | WO2016179534A2 (fr) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ731185A (en) | 2014-10-29 | 2024-03-22 | Bicyclerd Ltd | Bicyclic peptide ligands specific for mt1-mmp |
| CN110352068A (zh) | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| WO2018111976A1 (fr) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Domaines de fibronectine de type iii se liant à pd-l1 |
| KR102568559B1 (ko) | 2016-12-14 | 2023-08-18 | 얀센 바이오테크 인코포레이티드 | Cd8a-결합 섬유결합소 iii형 도메인 |
| WO2018111978A1 (fr) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Domaines de fibronectine de type iii à liaison au cd137 |
| WO2019002842A1 (fr) | 2017-06-26 | 2019-01-03 | Bicyclerd Limited | Ligands peptidiques bicycliques à fractions détectables et leurs utilisations |
| JP7280238B2 (ja) * | 2017-07-17 | 2023-05-23 | ヤンセン バイオテツク，インコーポレーテツド | フィブロネクチンｉｉｉ型ドメインに対する抗原結合領域及びその使用方法 |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Ｃｄ１３７に対して特異的な二環式ペプチドリガンド |
| CA3074317C (fr) * | 2017-08-25 | 2024-06-18 | Janssen Biotech, Inc. | Domaines de type iii de fibronectine liant fc.gamma.rii, leurs conjugues et molecules multispecifiques les comprenant |
| CA3082204A1 (fr) * | 2017-12-13 | 2019-06-20 | Janssen Biotech, Inc. | Lymphocytes car-t immortalises genetiquement modifies pour eliminer l'expression du recepteur des lymphocytes t et de la beta 2-microglobuline |
| US20190184028A1 (en) * | 2017-12-14 | 2019-06-20 | Janssen Biotech, Inc. | Targeting with firbronectin type iii like domain molecules |
| CA3091775A1 (fr) | 2018-02-23 | 2019-08-29 | Bicycletx Limited | Ligands peptidiques bicycliques multimeres |
| BR112020018049A2 (pt) * | 2018-03-07 | 2020-12-29 | Poseida Therapeutics, Inc. | Composições de cartirina e métodos para uso |
| MX2020012598A (es) | 2018-05-24 | 2021-05-27 | Janssen Biotech Inc | Agentes aglutinantes del psma y usos de estos. |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| GB201810325D0 (en) * | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to PSMA |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820325D0 (en) * | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| EP3898993A1 (fr) * | 2018-12-20 | 2021-10-27 | Poseida Therapeutics, Inc. | Compositions de nanotransposons et procédés d'utilisation |
| EP3897849A1 (fr) | 2018-12-21 | 2021-10-27 | BicycleTx Limited | Ligands peptidiques bicycliques spécifiques pour pd-l1 |
| WO2020128527A1 (fr) | 2018-12-21 | 2020-06-25 | Bicyclerd Limited | Ligands peptidiques bicycliques spécifiques à pd-l1 |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| US12611441B2 (en) * | 2019-04-10 | 2026-04-28 | Navigo Proteins Gmbh | PSMA specific binding proteins for cancer diagnosis and treatment |
| AR118720A1 (es) | 2019-04-19 | 2021-10-27 | Janssen Biotech Inc | Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
| CN114786682B (zh) | 2019-10-14 | 2024-07-16 | Aro生物疗法公司 | 结合cd71的纤维粘连蛋白iii型结构域 |
| WO2021076543A1 (fr) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Domaines de type iii de fibronectine de liaison à cd137 |
| CN115884778A (zh) * | 2020-05-05 | 2023-03-31 | Aro生物疗法公司 | 与前列腺特异性膜抗原结合的纤连蛋白iii型结构域和包含该结构域的细胞 |
| CN116348476A (zh) | 2020-08-03 | 2023-06-27 | 拜斯科技术开发有限公司 | 基于肽的接头 |
| JP2024517610A (ja) | 2021-04-14 | 2024-04-23 | アロ・バイオセラピューティクス・カンパニー | Ｃｄ７１に結合するフィブロネクチンｉｉｉ型ドメイン |
| KR20240031947A (ko) | 2021-04-14 | 2024-03-08 | 에이알오 바이오테라퓨틱스 컴패니 | Fn3 도메인-시르나 접합체 및 이의 용도 |
| WO2023026236A1 (fr) * | 2021-08-27 | 2023-03-02 | Janssen Biotech, Inc. | Radioconjugués anti-psma et leurs utilisations |
| WO2023026235A1 (fr) | 2021-08-27 | 2023-03-02 | Janssen Biotech, Inc. | Anticorps anti-psma et leurs utilisations |
| JPWO2023135944A1 (fr) | 2022-01-11 | 2023-07-20 | ||
| CN114940710B (zh) * | 2022-06-07 | 2023-09-26 | 恺佧生物科技(上海)有限公司 | 一种提高重组人psma蛋白表达的方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| ES2118066T3 (es) | 1989-10-05 | 1998-09-16 | Optein Inc | Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos. |
| US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| WO1994012520A1 (fr) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Segment de liaison pour polypeptides fusionnes lies |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ，インコーポレイティド | 人工抗体ポリペプチド |
| US5981209A (en) | 1997-12-04 | 1999-11-09 | Guilford Pharmaceuticals Inc. | Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia |
| US6472147B1 (en) | 1999-05-25 | 2002-10-29 | The Scripps Research Institute | Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries |
| US20130226834A1 (en) | 2000-04-27 | 2013-08-29 | Networth Services, Inc. | Systems and methods for determining the financial status of bonds |
| CA2418835A1 (fr) * | 2000-10-16 | 2002-04-25 | Phylos, Inc. | Echafaudages proteiniques internes pour analogues d'anticorps et autres proteines de liaison |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| EP1392648A1 (fr) | 2001-05-11 | 2004-03-03 | Guilford Pharmaceuticals Inc. | Acides hydroxamiques et hydroxamines d'acyle utilises comme inhibiteurs de naaladase |
| JP4602614B2 (ja) | 2001-09-26 | 2010-12-22 | アイシン精機株式会社 | 自動車用ドア |
| AU2003260786B2 (en) | 2002-09-06 | 2008-03-13 | Isogenica Limited | In vitro peptide expression libraray |
| AU2007325838B2 (en) | 2006-11-22 | 2013-09-19 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
| AU2008343589A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods |
| AU2008343595A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | A human non-antibody peptide or protein phage library |
| MX2011004550A (es) | 2008-10-31 | 2011-07-20 | Centocor Ortho Biotech Inc | Composiciones de de supercóntigos a base de dominios de fibronectina tipo iii, métodos y usos. |
| HUE029622T2 (en) | 2010-04-30 | 2017-03-28 | Janssen Biotech Inc | Stabilized fibronectin domain compositions, methods and uses |
| WO2012162418A1 (fr) * | 2011-05-23 | 2012-11-29 | The University Of North Carolina At Chapel Hill | Procédés et compositions pour ligands de ciblage hétérodimères |
| WO2013002362A1 (fr) * | 2011-06-30 | 2013-01-03 | 中外製薬株式会社 | Polypeptide hétérodimérisé |
| MX358827B (es) | 2011-09-27 | 2018-09-05 | Janssen Biotech Inc | Supercóntigos de proteína basados en repeticiones de fibronectina tipo iii con superficies de unión alternativas. |
| US9695228B2 (en) | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
| AU2014363987A1 (en) | 2013-12-09 | 2016-06-30 | Janssen Biotech, Inc. | Compositions and methods for phagocyte delivery of anti-staphylococcal agents |
| EA201792442A1 (ru) * | 2015-05-06 | 2018-06-29 | Янссен Байотек, Инк. | Биспецифические агенты, связывающие простатический специфический мембранный антиген (psma), и их применение |
-
2016
- 2016-05-06 JP JP2017557340A patent/JP7366518B2/ja active Active
- 2016-05-06 CA CA2985138A patent/CA2985138A1/fr active Pending
- 2016-05-06 AU AU2016258174A patent/AU2016258174B2/en active Active
- 2016-05-06 US US15/148,312 patent/US10844111B2/en active Active
- 2016-05-06 KR KR1020177034904A patent/KR102625793B1/ko active Active
- 2016-05-06 CN CN201680039974.8A patent/CN107849116A/zh active Pending
- 2016-05-06 WO PCT/US2016/031295 patent/WO2016179534A2/fr not_active Ceased
- 2016-05-06 EP EP16790187.5A patent/EP3292222B1/fr active Active
- 2016-05-06 EA EA201792441A patent/EA201792441A2/ru unknown
- 2016-05-06 IL IL255425A patent/IL255425B2/en unknown
- 2016-05-06 HK HK18112371.4A patent/HK1253005A1/zh unknown
- 2016-05-06 MA MA042060A patent/MA42060A/fr unknown
-
2020
- 2020-10-13 US US16/949,078 patent/US12054534B2/en active Active
-
2021
- 2021-09-27 JP JP2021156739A patent/JP7307133B2/ja active Active
-
2022
- 2022-04-20 AU AU2022202637A patent/AU2022202637A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016258174A1 (en) | 2017-11-23 |
| JP7307133B2 (ja) | 2023-07-11 |
| EA201792441A2 (ru) | 2018-06-29 |
| IL255425B2 (en) | 2023-10-01 |
| WO2016179534A2 (fr) | 2016-11-10 |
| BR112017023798A2 (en) | 2018-10-16 |
| HK1253005A1 (zh) | 2019-06-06 |
| JP2022002526A (ja) | 2022-01-11 |
| CA2985138A1 (fr) | 2016-11-10 |
| KR102625793B1 (ko) | 2024-01-15 |
| AU2022202637A1 (en) | 2022-05-12 |
| CN107849116A (zh) | 2018-03-27 |
| JP2018515087A (ja) | 2018-06-14 |
| KR20180002780A (ko) | 2018-01-08 |
| JP7366518B2 (ja) | 2023-10-23 |
| US12054534B2 (en) | 2024-08-06 |
| IL255425A0 (en) | 2017-12-31 |
| EP3292222A4 (fr) | 2018-10-17 |
| EP3292222B1 (fr) | 2025-09-03 |
| IL255425B1 (en) | 2023-06-01 |
| AU2016258174B2 (en) | 2022-01-20 |
| US10844111B2 (en) | 2020-11-24 |
| EP3292222A2 (fr) | 2018-03-14 |
| US20210147510A1 (en) | 2021-05-20 |
| US20160326232A1 (en) | 2016-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20181802T1 (hr) | Protutijela koja vežu humani cd3 | |
| IL255424A0 (en) | Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof | |
| IL265321B1 (en) | Cd3 binding antibodies | |
| IL256562A (en) | Humanized or chimeric cd3 antibodies | |
| IL263840A (en) | Cd3 binding antibodies | |
| DK3625259T3 (da) | Anti-sirpalpha-antistoffer | |
| EP3661558A4 (fr) | Anticorps anti-il1rap | |
| EP3461261A4 (fr) | Protéines se liant au fragment monocaténaire variable de cd3 | |
| EP3569709A4 (fr) | Anticorps anti-gpc3 | |
| EP3498840A4 (fr) | Anticorps anti-lag-3 | |
| EP3423089A4 (fr) | Anticorps anti-tigit | |
| PL3449940T3 (pl) | Preparat zawierający przeciwciała | |
| IL290449A (en) | Antibody-mediated neutralization of chikungunya virus | |
| EP3691447A4 (fr) | Anticorps anti-transthyrétine | |
| DK3242892T3 (da) | Modificerede april-bindende antistoffer | |
| EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
| EP3400229A4 (fr) | Composés marqués au 18/19f qui ciblent l'antigène membranaire spécifique de la prostate | |
| EP3325963A4 (fr) | Amélioration de l'estimation de globules | |
| IL262776A (en) | Humanized anti-il-1r3 antibodies | |
| DK3606961T3 (da) | Garp-tgf-beta-antistoffer | |
| EA201691610A8 (ru) | Анти-jagged1 антитела и способы применения | |
| IL268731A (en) | New uses of anti-sirpg antibodies | |
| MA53248A (fr) | Anticorps anti-c5 à commutation ph améliorée | |
| EP3492591A4 (fr) | Anticorps anti-b7-h4 | |
| EP3526247A4 (fr) | Anticorps anti-il1-rap |